Weekly Docetaxel Versus Weekly Docetaxel/Gemcitabine in the Treatment of Non-Small Cell Lung Cancer in Elderly Patients
Completed · Phase 2
Conditions studied: Lung Cancer
In brief
In this randomized trial, we attempt to further define optimal palliative chemotherapy for elderly patients with advanced non-small cell lung cancer by comparing single agent treatment with weekly docetaxel versus combination therapy with weekly docetaxel plus gemcitabine.
Key facts
- Study ID
- NCT00193323
- Run by
- SCRI Development Innovations, LLC
- People needed
- 346
- Starts
- 2001-08-01
- Expected to finish
- 2009-01-01
- Last updated by the study team
- 2010-06-28
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- To be included in this study, you must meet the following criteria:
- Biopsy-proven non-small cell lung cancer
- No previous chemotherapy.
- Age > 65 years
- Age < 65 years requires significant assistance to perform activities of daily
- Stage IV disease or stage IIIB disease
- Ability to perform activities of daily living with minimal assistance
- Measurable or evaluable disease
- Adequate bone marrow, liver and kidney
- All patients must sign written informed consent prior to study entry.
You may not qualify if…
- You cannot participate in this study if any of the following apply to you:
- Brain metastases
- Meningeal metastases
- Other uncontrolled malignancies
- History of invasive cancer during the last 5 years
- Moderate to severe peripheral neuropathy
- Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.
Where it is running
- Tennessee Oncology, PLLC — Nashville, Tennessee, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.